Biotechnology
How drugs get into the blood
Research
ETH Zurich
Computer simulations have helped researchers understand in detail how pharmaceutically active substances cross cell membranes. These findings can now be used to discover new drug candidates more efficiently.
Nanoplasmonic imaging reveals real-time protein secretion
Research
EPFL
EPFL researchers have used a nanoplasmonics approach to observe the real-time production of cell secretions, including proteins and antibodies; an advancement that could aid in the development of cancer treatments, vaccines, and other therapies.
Generating power with blood sugar
Research
ETH Zurich
A fuel cell under the skin that converts blood sugar from the body into electrical energy sounds like science fiction. Yet it works perfectly, as an ETH Zurich research team led by Martin Fussenegger, Professor of Biotechnology and Bioengineering, has shown.
Immune-cell booster for cancer patients
Research
ETH Zurich
Cancer patients might one day benefit from being administered immune cells from healthy donors. But as things stand, receiving donor cells can cause severe or even fatal immune reactions. A researcher at ETH Zurich has now developed a technology that avoids these.
Scientists unlock nature's secret to super-selective binding
Research
EPFL
EPFL researchers have discovered that it is not just molecular density, but also pattern and structural rigidity, that control super-selective binding interactions between nanomaterials and protein surfaces. The breakthrough could help optimize existing approaches to virus prevention and cancer detection.
The protein behind immunotherapy resistance
Research
EPFL
Scientists at EPFL, Ludwig Institute of Cancer Research, and CHUV have identified a key protein that helps tumors evade attacks by the immune system, contributing to poor responses to immunotherapy in the clinic.
Page 4 of 9